Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Biotech Podcast: Going Global Trends, Rare Disease Drug Development

Internationalization 'A Must' for China Biotechs

Executive Summary

Guest speaker Professor Guangzuo Luo joins Brian Yang and Dexter Yang to discuss orphan drug development and going global trends for Chinese bioventures, along with the latest business moves from Shanghai Fosun and Jiangsu Hengrui.

This time, Guangzuo Luo, founder and chief scientific officer of Nanjing-based Bioncetech, joins China-based Scrip editors Brian Yang and Dexter Yan in this Chinese-language podcast to talk about his views on the challenges and opportunities around developing orphan drugs in China. 

Luo is also a professor at China Medical University and has years of experience developing gene therapies, including the first US-approved adeno-associated virus-based gene therapy, Spark Therapeutics, Inc.'s Luxturna (voretigene neparvovec) for an inherited retinal disease. 

He also discusses Bioncetech's pipeline, which includes candidates for common conditions.

In the second part of the podcast, Brian talks about his coverage of recent moves by Jiangsu Hengrui Medicine Co., Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to go global.

He highlights the three main options for Chinese biotechs pursuing internationalization, other recent trends and how a full acquisition of  Shanghai Henlius Biotech Co. Ltd. by Fosun might benefit the latter’s overseas expansion goals.

罗光佐教授是贝思奥生物创始人董事长,中国医科大学教授、博导,美国宾夕法尼亚大学博士后,中国科学院遗传学博士。他的丰富行业经验包括世界上第一例上市的AAV基因治疗起源地宾大(Upenn)、CHOP和基因治疗公司Spark Therapeutics 。



Stories discussed in this podcast:

(Also see "China Rare Disease Firms Aspire To Global Stage" - Scrip, 30 May, 2024.)

(Also see "Fosun To Fully Acquire Henlius In Go-Global Push?" - Scrip, 26 May, 2024.)

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts